Making foods more filling could help tackle obesityAdding a chemical that helps to cause satedness after eating to food may help to reduce the amount that individuals eat and therefore reduce weight gain.…
Shire announces US$5.2bn acquisition of NPS PharmaceuticalsShire has announced a US$5.2bn acquisition of the US company NPS Pharmaceuticals following unanimous approval by both company boards.…
2014: The Pharmaceutical Journal’s news in review Looking back at some of the biggest news stories from the past year. …
Assessing suspected food poisoning cases in the UK With more than 20,000 patients hospitalised in the UK each year because of food poisoning, quick assessment is essential.…
BNF revises domperidone advice and introduces new monoclonal antibody Children and their carers who use domperidone for gastro-oesophageal reflux disease should be told how to recognise symptoms of arrhythmia, according to the latest update from the British National Formulary.…
Research confirms faecal microbiota transplantation is safe and effective An age-old treatment has shown remarkable clinical cure rates for Clostridium difficile infection, achieving far better outcomes than antimicrobial therapy.…
Regulator rejects call for stricter control of laxative sales A call by an eating disorder charity for tougher controls on the sale of laxatives has been rejected by the Medicines and Healthcare products Regulatory Agency.…
Faecal transplant therapy delivered effectively by oral capsule Oral delivery of faecal microbiota to eliminate Clostridium difficile infection is as successful as more invasive methods of the treatment.…
OTC domperidone will be missedThe antiemetic domperidone’s reclassification shows the importance of pharmacovigilance, but the loss of such a useful over-the-counter medicine ought to have been better communicated to community pharmacies.…
Domperidone must be supplied on prescription, MHRA rules Domperidone (Motilium), used to treat nausea and vomiting, will be a prescription-only medicine from 4 September 2014.…
